Patents by Inventor John W. Blankenship
John W. Blankenship has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11939392Abstract: The present disclosure relates to protein molecules that specifically bind to CD123, which may have at least one humanized or human CD123-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD123 may have a second binding domain that binds to another target. In one embodiment, multi-specific polypeptide molecules bind both CD123-expressing cells and the T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD123-binding polypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.Type: GrantFiled: December 21, 2021Date of Patent: March 26, 2024Assignee: Aptevo Research and Development LLCInventors: Gabriela Hernandez-Hoyos, Elaine T. Sewell, Catherine J. McMahan, David Bienvenue, John W. Blankenship, Danielle Mitchell, Peter Pavlik
-
Publication number: 20220363773Abstract: The present disclosure relates to protein molecules that specifically bind to CD123, which may have at least one humanized or human CD123-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD123 may have a second binding domain that binds to another target. In one embodiment, multi-specific polypeptide molecules bind both CD123-expressing cells and the T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD123-binding polypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.Type: ApplicationFiled: December 21, 2021Publication date: November 17, 2022Inventors: Gabriela HERNANDEZ-HOYOS, Elaine T. SEWELL, Catherine J. MCMAHAN, David BIENVENUE, John W. BLANKENSHIP, Danielle MITCHELL, Peter PAVLIK
-
Patent number: 11352426Abstract: The present disclosure relates to protein molecules that specifically bind to CD3, which may have at least one humanized CD3-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD3 may have a second binding domain that binds to another target. In one embodiment, multispecific polypeptide molecules bind both tumor antigen-expressing cells and the CD3 subunit of a T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD3-binding poypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.Type: GrantFiled: September 21, 2016Date of Patent: June 7, 2022Assignee: APTEVO RESEARCH AND DEVELOPMENT LLCInventors: Philip Tan, John W. Blankenship
-
Patent number: 11242400Abstract: The present disclosure relates to protein molecules that specifically bind to CD123, which may have at least one humanized or human CD123-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD123 may have a second binding domain that binds to another target. In one embodiment, multi-specific polypeptide molecules bind both CD123-expressing cells and the T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD123-binding polypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.Type: GrantFiled: September 21, 2017Date of Patent: February 8, 2022Assignee: Aptevo Research and Development LLCInventors: Gabriela Hernandez-Hoyos, Elaine T. Sewell, Catherine J. McMahan, David Bienvenue, John W. Blankenship, Danielle Mitchell, Peter Pavlik
-
Publication number: 20210095046Abstract: The present invention relates to mono-specific and multi-specific polypeptide therapeutics that specifically target cells expressing prostate-specific membrane antigen (PSMA) and are useful for the treatment of prostate cancer (e.g., castrate-resistant prostate cancer), tumor-related angiogenesis or benign prostatic hyperplasia (BPH). In one embodiment, the multi-specific polypeptide therapeutics bind both PSMA-expressing cells and the T-cell receptor complex on T cells to induce target-dependent T-cell cytotoxicity, activation and proliferation.Type: ApplicationFiled: May 11, 2020Publication date: April 1, 2021Inventors: John W. BLANKENSHIP, Elaine Todd SEWELL, Philip TAN
-
Patent number: 10676533Abstract: The present disclosure relates to protein molecules that specifically bind to CD123, which may have at least one humanized or human CD123-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD123 may have a second binding domain that binds to another target. In one embodiment, multi-specific polypeptide molecules bind both CD123-expressing cells and the T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD123-binding polypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.Type: GrantFiled: March 22, 2018Date of Patent: June 9, 2020Assignee: Aptevo Research and Development LLCInventors: Gabriela Hernandez-Hoyos, Elaine T. Sewell, Catherine J. McMahan, David Bienvenue, John W. Blankenship, Danielle Mitchell, Peter Pavlik
-
Publication number: 20200165346Abstract: The present disclosure relates to protein molecules that specifically bind to CD123, which may have at least one humanized or human CD123-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD123 may have a second binding domain that binds to another target. In one embodiment, multi-specific polypeptide molecules bind both CD123-expressing cells and the T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD123-binding polypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.Type: ApplicationFiled: September 21, 2017Publication date: May 28, 2020Inventors: Gabriela Hernandez-Hoyos, Elaine T. Sewell, Catherine J. McMahan, David Bienvenue, John W. Blankenship, Danielle Mitchell, Peter Pavlik
-
Publication number: 20190071513Abstract: The present disclosure relates to protein molecules that specifically bind to CD123, which may have at least one humanized or human CD123-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD123 may have a second binding domain that binds to another target. In one embodiment, multi-specific polypeptide molecules bind both CD123-expressing cells and the T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD123-binding polypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.Type: ApplicationFiled: March 22, 2018Publication date: March 7, 2019Inventors: Gabriela Hernandez-Hoyos, Elaine T. Sewell, Catherine J. McMahan, David Bienvenue, John W. Blankenship, Danielle Mitchell, Peter Pavlik
-
Publication number: 20180273622Abstract: The present disclosure relates to protein molecules that specifically bind to CD3, which may have at least one humanized CD3-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD3 may have a second binding domain that binds to another target. In one embodiment, multispecific polypeptide molecules bind both tumor antigen-expressing cells and the CD3 subunit of a T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD3-binding poypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.Type: ApplicationFiled: September 21, 2016Publication date: September 27, 2018Inventors: Philip Tan, John W. Blankenship
-
Publication number: 20180273642Abstract: The present disclosure provides polypeptide heterodimers formed between two different single chain fusion polypeptides via natural heterodimerization of an immunoglobulin CH1 region and an immunoglobulin light chain constant region (CL). The polypeptide heterodimer comprises two or more binding domains that specifically bind one or more targets (e.g., a receptor). In addition, both chains of the heterodimer further comprise an Fc region portion. The present disclosure also provides nucleic acids, vectors, host cells and methods for making polypeptide heterodimers as well as methods for using such polypeptide heterodimers, such as in directing T cell activation, inhibiting solid malignancy growth, and treating autoimmune or inflammatory conditions.Type: ApplicationFiled: November 3, 2017Publication date: September 27, 2018Inventors: John W. Blankenship, Philip Tan
-
Publication number: 20180100021Abstract: The present invention relates to mono-specific and multi-specific polypeptide therapeutics that specifically target cells expressing prostate-specific membrane antigen (PSMA) and are useful for the treatment of prostate cancer (e.g., castrate-resistant prostate cancer), tumor-related angiogenesis or benign prostatic hyperplasia (BPH). In one embodiment, the multi-specific poly-peptide therapeutics bind both PSMA-expressing cells and the T-cell receptor complex on T cells to induce target-dependent T-cell cytotoxicity, activation and proliferation.Type: ApplicationFiled: September 8, 2017Publication date: April 12, 2018Inventors: John W. BLANKENSHIP, Elaine Todd SEWELL, Philip TAN
-
Publication number: 20170306045Abstract: The present invention relates to mono-specific and multi-specific polypeptide therapeutics that specifically target cells expressing prostate-specific membrane antigen (PSMA) and are useful for the treatment of prostate cancer (e.g., castrate-resistant prostate cancer), tumor-related angiogenesis or benign prostatic hyperplasia (BPH). In one embodiment, the multi-specific polypeptide therapeutics bind both PSMA-expressing cells and the T-cell receptor complex on T cells to induce target-dependent T-cell cytotoxicity, activation and proliferation.Type: ApplicationFiled: May 3, 2017Publication date: October 26, 2017Inventors: John W. BLANKENSHIP, Elaine Todd SEWELL, Philip TAN
-
Patent number: 9782478Abstract: The present invention relates to mono-specific and multi-specific polypeptide therapeutics that specifically target cells expressing prostate-specific membrane antigen (PSMA) and are useful for the treatment of prostate cancer (e.g., castrate-resistant prostate cancer), tumor-related angiogenesis or benign prostatic hyperplasia (BPH). In one embodiment, the multi-specific polypeptide therapeutics bind both PSMA-expressing cells and the T-cell receptor complex on T cells to induce target-dependent T-cell cytotoxicity, activation and proliferation.Type: GrantFiled: May 3, 2017Date of Patent: October 10, 2017Assignee: Aptevo Research and Development LLCInventors: John W. Blankenship, Elaine Todd Sewell, Philip Tan
-
Publication number: 20170015747Abstract: This disclosure provides a multi-specific fusion protein composed of a CD86 antagonist binding domain and another binding domain that is an IL-10 agonist, an HLA-G agonist, an HGF agonist, an IL-35 agonist, a PD-1 agonist, a BTLA agonist, a LIGHT antagonist, a GITRL antagonist or a CD40 antagonist. The multi-specific fusion protein may also include an intervening domain that separates the other domains. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.Type: ApplicationFiled: September 30, 2016Publication date: January 19, 2017Inventors: Peter Armstrong Thompson, Peter Robert Baum, Philip Tan, John W. Blankenship, Sateesh Kumar Natarajan
-
Publication number: 20170008960Abstract: Single chain fusion proteins that specifically bind to a TCR complex or a component thereof, such as TCR?, TCR?, or CD3?, along with compositions and methods of use thereof are provided.Type: ApplicationFiled: February 10, 2016Publication date: January 12, 2017Inventors: Valerie Odegard, Catherine J. McMahan, Peter Robert Baum, Peter Armstrong Thompson, Philip Tan, John W. Blankenship, Sateesh Kumar Natarajan
-
Patent number: 9493564Abstract: This disclosure provides a multi-specific fusion protein composed of a CD86 antagonist binding domain and another binding domain that is an IL-10 agonist, an HLA-G agonist, an HGF agonist, an IL-35 agonist, a PD-1 agonist, a BTLA agonist, a LIGHT antagonist, a GITRL antagonist or a CD40 antagonist. The multi-specific fusion protein may also include an intervening domain that separates the other domains. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.Type: GrantFiled: October 2, 2009Date of Patent: November 15, 2016Assignee: APTEVO RESEARCH AND DEVELOPMENT LLCInventors: Peter Armstrong Thompson, Peter Robert Baum, Philip Tan, John W. Blankenship, Sateesh Kumar Natarajan
-
Publication number: 20150274844Abstract: The present disclosure provides polypeptide heterodimers formed between two different single chain fusion polypeptides via natural heterodimerization of an immunoglobulin CH1 region and an immunoglobulin light chain constant region (CL). The polypeptide heterodimer comprises two or more binding domains that specifically bind one or more targets (e.g., a receptor). In addition, both chains of the heterodimer further comprise an Fc region portion. The present disclosure also provides nucleic acids, vectors, host cells and methods for making polypeptide heterodimers as well as methods for using such polypeptide heterodimers, such as in directing T cell activation, inhibiting solid malignancy growth, and treating autoimmune or inflammatory conditions.Type: ApplicationFiled: March 6, 2015Publication date: October 1, 2015Inventors: John W. Blankenship, Philip Tan
-
Publication number: 20140161800Abstract: The present invention relates to mono-specific and multi-specific polypeptide therapeutics that specifically target cells expressing prostate-specific membrane antigen (PSMA) and are useful for the treatment of prostate cancer (e.g., castrate-resistant prostate cancer), tumor-related angiogenesis or benign prostatic hyperplasia (BPH). In one embodiment, the multi-specific polypeptide therapeutics bind both PSMA-expressing cells and the T-cell receptor complex on T cells to induce target-dependent T-cell cytotoxicity, activation and proliferation.Type: ApplicationFiled: April 20, 2012Publication date: June 12, 2014Inventors: John W. Blankenship, Elaine Todd Sewell, Philip Tan
-
Publication number: 20130129723Abstract: The present disclosure provides polypeptide heterodimers formed between two different single chain fusion polypeptides via natural heterodimerization of an immunoglobulin CH1 region and an immunoglobulin light chain constant region (CL). The polypeptide heterodimer comprises two or more binding domains that specifically bind one or more targets (e.g., a receptor). In addition, both chains of the heterodimer further comprise an Fc region portion. The present disclosure also provides nucleic acids, vectors, host cells and methods for making polypeptide heterodimers as well as methods for using such polypeptide heterodimers, such as in directing T cell activation, inhibiting solid malignancy growth, and treating autoimmune or inflammatory conditions.Type: ApplicationFiled: December 29, 2010Publication date: May 23, 2013Applicant: Emergent Product Development Seattle, LLCInventors: John W. Blankenship, Philip Tan
-
Publication number: 20130095097Abstract: The present disclosure provides polypeptide heterodimers formed between two different single chain fusion polypeptides via natural heterodimerization of an immunoglobulin CH1 region and an immunoglobulin light chain constant region (CL). One chain of a heterodimer comprises a binding domain that specifically binds a target (e.g., a receptor). In addition, both chains of a heterodimer further comprise an Fc region portion. The present disclosure also provides nucleic acids, vectors, host cells and methods for making polypeptide heterodimers as well as methods for using such polypeptide heterodimers, such as in reducing T cell activation, inhibiting solid malignancy growth, and treating autoimmune or inflammatory conditions.Type: ApplicationFiled: December 29, 2010Publication date: April 18, 2013Applicant: Emergent Product Development Seattle, LLCInventors: John W. Blankenship, Philip Tan